1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Degenerative Disc Disease - Pipeline Review, H1 2016

Degenerative Disc Disease - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 80 pages

Degenerative Disc Disease - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Degenerative Disc Disease - Pipeline Review, H1 2016’, provides an overview of the Degenerative Disc Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease
- The report reviews pipeline therapeutics for Degenerative Disc Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Degenerative Disc Disease therapeutics and enlists all their major and minor projects
- The report assesses Degenerative Disc Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Degenerative Disc Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Degenerative Disc Disease - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Degenerative Disc Disease Overview 8
Therapeutics Development 9
Pipeline Products for Degenerative Disc Disease - Overview 9
Pipeline Products for Degenerative Disc Disease - Comparative Analysis 10
Degenerative Disc Disease - Therapeutics under Development by Companies 11
Degenerative Disc Disease - Therapeutics under Investigation by Universities/Institutes 12
Degenerative Disc Disease - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Degenerative Disc Disease - Products under Development by Companies 17
Degenerative Disc Disease - Products under Investigation by Universities/Institutes 18
Degenerative Disc Disease - Companies Involved in Therapeutics Development 19
AnGes MG, Inc. 19
Biogenomics Limited 20
Biopharm GmbH 21
BioRestorative Therapies, Inc. 22
Bone Therapeutics SA 23
DiscGenics, Inc. 24
ISTO Technologies, Inc. 25
K-Stemcell Co., Ltd. 26
Mesoblast Limited 27
TissueGene, Inc. 28
U.S. Stem Cell, Inc. 29
Yuhan Corporation 30
Degenerative Disc Disease - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AdipoCell - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
ALLOB - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
AMG-0103 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
BRTX-100 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
CHND-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
dibotermin alfa - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
MPC-25Osteo - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
NuQu - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Poly N-Acetyl Glucosamine Hydrogel - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
S-414114 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Small Molecules for Degenerative Disc Disease - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
TG-D - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
YH-14618 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Degenerative Disc Disease - Recent Pipeline Updates 66
Degenerative Disc Disease - Dormant Projects 72
Degenerative Disc Disease - Product Development Milestones 73
Featured News and Press Releases 73
Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product 73
Jul 27, 2015: Denver Back Pain Specialists Physicians Begin Enrollment in Stem Cell Therapy Study in Subjects with Chronic Back Pain 73
Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA 74
Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA 74
Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease 75
Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies 75
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion 76
Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease 76
Jan 29, 2014: Positive Spinal Disc Repair Trial Results Using Mesoblast Adult Stem Cells 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables
Number of Products under Development for Degenerative Disc Disease, H1 2016 9
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Comparative Analysis by Unknown Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H1 2016 19
Degenerative Disc Disease - Pipeline by Biogenomics Limited, H1 2016 20
Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1 2016 21
Degenerative Disc Disease - Pipeline by BioRestorative Therapies, Inc., H1 2016 22
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2016 23
Degenerative Disc Disease - Pipeline by DiscGenics, Inc., H1 2016 24
Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H1 2016 25
Degenerative Disc Disease - Pipeline by K-Stemcell Co., Ltd., H1 2016 26
Degenerative Disc Disease - Pipeline by Mesoblast Limited, H1 2016 27
Degenerative Disc Disease - Pipeline by TissueGene, Inc., H1 2016 28
Degenerative Disc Disease - Pipeline by U.S. Stem Cell, Inc., H1 2016 29
Degenerative Disc Disease - Pipeline by Yuhan Corporation, H1 2016 30
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Degenerative Disc Disease Therapeutics - Recent Pipeline Updates, H1 2016 66
Degenerative Disc Disease - Dormant Projects, H1 2016 72

List of Figures
Number of Products under Development for Degenerative Disc Disease, H1 2016 9
Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Targets, H1 2016 32
Number of Products by Stage and Targets, H1 2016 32
Number of Products by Mechanism of Actions, H1 2016 34
Number of Products by Stage and Mechanism of Actions, H1 2016 34
Number of Products by Routes of Administration, H1 2016 36
Number of Products by Stage and Routes of Administration, H1 2016 36
Number of Products by Molecule Types, H1 2016 38
Number of Products by Stage and Molecule Types, H1 2016 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.